[go: up one dir, main page]

TN2009000504A1 - Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray - Google Patents

Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray

Info

Publication number
TN2009000504A1
TN2009000504A1 TNP2009000504A TN2009000504A TN2009000504A1 TN 2009000504 A1 TN2009000504 A1 TN 2009000504A1 TN P2009000504 A TNP2009000504 A TN P2009000504A TN 2009000504 A TN2009000504 A TN 2009000504A TN 2009000504 A1 TN2009000504 A1 TN 2009000504A1
Authority
TN
Tunisia
Prior art keywords
dispenser
formulation
spray
agents
pharmaceutical formulation
Prior art date
Application number
TNP2009000504A
Other languages
French (fr)
Inventor
Anna E Gluskin
Muhammad Waseem Tahir Qazi
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of TN2009000504A1 publication Critical patent/TN2009000504A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0625—Mouth
    • A61M2210/065—Throat; Pharynx

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical formulation delivered as a spray from a metered dose dispenser into the oral cavity for absorption through oral mucosa, comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) a micelle- forming compound that is an alkali metal alkyl sulfate or a polyoxyethylene sorbitan monooleate, (c) a block copolymer of polyoxyethylene and polyoxypropylene, (d) at least one additional micelle¬forming compound, and ( e) a suitable solven. The invention also provides a dispenser containing the present formulation, and a method of administering this formulation comprising insulin as the pharmaceutical agent, where a dose of the formulation is split to be administered before and after each meal.
TNP2009000504A 2007-07-30 2009-11-30 Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray TN2009000504A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2007/001345 WO2009015456A1 (en) 2007-07-30 2007-07-30 Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray

Publications (1)

Publication Number Publication Date
TN2009000504A1 true TN2009000504A1 (en) 2011-03-31

Family

ID=40303827

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000504A TN2009000504A1 (en) 2007-07-30 2009-11-30 Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray

Country Status (2)

Country Link
TN (1) TN2009000504A1 (en)
WO (1) WO2009015456A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3141246A1 (en) 2009-08-31 2017-03-15 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
CN103596584B (en) 2011-06-15 2016-12-14 诺沃—诺迪斯克有限公司 Polysubstituted insulin
AR099569A1 (en) 2014-02-28 2016-08-03 Novo Nordisk As INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US11166912B2 (en) 2016-03-03 2021-11-09 Ctt Pharma Inc. Orally administrable composition
WO2020095175A1 (en) * 2018-11-07 2020-05-14 3M Innovative Properties Company Actuator housing for inhaler device
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
FR3107039B1 (en) * 2020-02-07 2022-03-18 Aptar France Sas Metering valve with improved metering chamber
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200800979A1 (en) * 2005-11-30 2008-10-30 Дженерекс Фармасьютикалз Инк. ORAL ABSORBED PHARMACEUTICAL COMPOSITION AND METHOD OF INTRODUCTION

Also Published As

Publication number Publication date
WO2009015456A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
TN2009000504A1 (en) Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
ECSP088403A (en) PHARMACEUTICAL FORMULATION OF ORAL ABSORPTION AND ITS METHOD OF ADMINISTRATION
AR059350A1 (en) PHARMACEUTICAL FORMULATION FOR AEROSOLS WITH TWO OR MORE ACTIVE PRINCIPLES AND AT LEAST A TENSIOACTIVE SUBSTANCE
MX335944B (en) Compositions comprising salbutamol sulphate.
MXPA03010791A (en) Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways.
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
MX2009009131A (en) Improvements in and relating to medicinal compositions.
TW200500098A (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
MX2010008234A (en) Novel dosage and formulation.
WO2004016244A3 (en) Pharmaceutical compositions for buccal delivery of pain relief medications
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
WO2007134292A3 (en) Treprostinil administration using a metered dose inhaler
WO2004105694A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
MX2009009132A (en) Improved medicinal compositions comprising buprenorphine and naltrexone.
WO2006058249A3 (en) Methods and compositions for deterring abuse of orally administered pharmaceutical products
MX336225B (en) Compositions comprising salbutamol sulphate.
EA201190127A1 (en) PHARMACEUTICAL COMPOSITIONS OF NITAZOXANIDE WITH CONTROLLED DELIVERY
NZ588913A (en) Liver cancer drug
WO2010103544A3 (en) A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
MX2010008235A (en) Novel dosage and formulation.
MX2015014513A (en) Composition comprising salbutamol sulphate.
MX2010004556A (en) Pharmaceutical formulation of clavulanic acid.
WO2008106689A3 (en) Breakthrough pain management
MX2009009134A (en) Improved medicinal compositions comprising buprenorphine and nalmefene.
WO2010044097A3 (en) Novel dosage form of paliperidone and process for preparing the same